AbbVie, schizophrenia

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie said that its Phase 2 trial investigating emraclidine as a once-daily oral monotherapy treatment for adults with schizophrenia did not meet the primary endpoint of showing a “statistically significant” improvement when compared with a placebo group.
AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials
In contrast to AbbVie’s woes, KarXT appears to be flourishing, with Zai Lab recently presenting data from a Phase III schizophrenia trial showing that KarXT met its primary endpoint, with a significant 9.2-point reduction in the PANSS total score ...
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy.
AbbVie under pressure as schizophrenia drug fails two trials
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company lost 12.6% on Monday in response to the disappointing news. However, Bristol Myers’ BMY stock was up 10.
Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
BioSpace4d
AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
FierceBiotech4d
AbbVie's $9B schizophrenia prospect flunks phase 2 trials, handing advantage to BMS
Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...
Zai Lab presents data from Phase 3 of KarXT for schizophrenia in China
Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of ...
Morningstar4d
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
The drug, previously called KarXT, is an oral medication for the treatment of schizophrenia in adults. Cobenfy introduces a fundamentally new approach to treating schizophrenia by selectively ...
ndtvprofit3d
Neuland Labs Share Price Hits Record High As KarXT Gains Focus After AbbVie Drug Setback
Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...
Cambridge University Press7d
Schizophrenia – new treatments soon
A number of questions remain to be answered in relation to this new class of muscarinic treatments for schizophrenia and psychosis. First, will they be effective for all people, or will only some ...
Business Wire17d
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
0.7 placebo, p=0.0062). There were no safety signals that were new or unexpected in comparison with prior KarXT trials in schizophrenia. Treatment emergent adverse events in the treatment arm that ...
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...